The new HP injectable manufacturing line, with an annual capacity of 12 million units, further enhances the company’s manufacturing capabilities
WuXi STA has launched its first high potency (HP), fully automated sterile injectable manufacturing line at its drug product site in Wuxi City, China.
The new HP injectable manufacturing line, with an annual capacity of 12 million units, further enhances the company’s manufacturing capabilities and capacity for injectable dosage forms – providing greater flexibility to respond to the increasing demand of the high potency pharmaceuticals market.
The new HP injectable manufacturing line meets Occupational Exposure Limits (OEL) as low as 10 ng/m3 and utilises fully enclosed isolation systems and automated filling machines. This design minimises human intervention, preventing cross-contamination and ensuring stringent quality assurance for sterile products. The line is equipped with two 20 m2 lyophilisers and supports liquid and lyophilised vials of various specifications, with a filling rate of up to 200 units per minute.
Adhering to the International Society for Pharmaceutical Engineering (ISPE) guidelines, regular industrial hygiene monitoring is conducted to maintain the integrity of the sealed isolators. This commitment to stringent compliance, along with the integration of an independent air conditioning system and a bag-in bag-out (BIBO) exhaust air purification system, guarantees the safety of operators, the environment, and the product quality.
The Wuxi City drug product site currently has two fully automated sterile injectable manufacturing lines, with manufacturing capacity of 2 million and 10 million units annually. These lines support various dosage forms, including liquid and lyophilised vials, pre-filled syringes, and cartridges.
In addition, the company's sterile lipid nanoparticle (LNP) platform has also started operation at the Wuxi City site, with a batch production capacity ranging from 10 to 50 litres, supporting the formulation development of complex new modalities, especially oligonucleotide-based drug candidates.
In addressing the growing needs of high potency drugs, WuXi STA, as an innovation enabler, will continue to strengthen our CRDMO platform capabilities
- Dr Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA
By 2024, WuXi STA plans to add two more injectable manufacturing lines at the same site, with additional lines to be added in Couvet, Switzerland and at the upcoming Middletown site in Delaware, USA.
The ongoing enhancement of injectable capabilities complements the WuXi TIDES CRDMO platform, providing integrated CMC solutions for both API and drug products spanning oligonucleotides, peptides, and related complex chemical conjugates.
To date, WuXi TIDES has gained experience from over 30 integrated CMC projects related to oligonucleotide and peptide drugs. The completed projects have demonstrated notable speed and efficiency advantages, typically progressing from API process development to IND-ready within a 9-10 month timeframe.
WuXi STA has established comprehensive capabilities in R&D and production of HPAPIs with many years of experience. Through the launch of the new HP injectable line, combined with its HP oral drug production line, the company further enhanced its HP CMC platform, providing an end-to-end solution including both API and drug product from development to commercial delivery.
“I’m thrilled that our HP injectable R&D and manufacturing platform has achieved yet another significant milestone,” said Dr Minzhang Chen, Co-CEO of WuXi AppTec and CEO of WuXi STA.
“In addressing the growing needs of high potency drugs, WuXi STA, as an innovation enabler, will continue to strengthen our CRDMO platform capabilities. With our proven track record of consistent quality and EHS systems across all sites globally, we are committed to accelerating pharmaceutical development and bringing new therapeutics for patients worldwide,” continued Chen.